Medical Condition News

RSS

Stress hormones may suppress tumor growth: Study

Chronic stress triggers a chain of molecular events that protects breakaway ovarian cancer cells from destruction, a team of researchers led by scientists at The University of Texas M. D. Anderson Cancer Center reports April 12 in the early online publication of the Journal of Clinical Investigation.

13 Apr 2010

Compound that kills specific lymphoma cells discovered

An international research team co-led by the Ontario Cancer Institute has discovered a compound that kills specific lymphoma cells - a discovery that will accelerate developing targeted drugs to fight the most common form of non-Hodgkins lymphoma.

13 Apr 2010

Gene mutations may predispose individuals to schizophrenia, says new study

An international study led by Universit- de Montr-al scientists suggests that gene mutations may predispose some individuals to schizophrenia and provides new clues about the causes of this ambiguous disorder.

13 Apr 2010

New endoscopic scanning technique improves early detection of dysplasia in Barrett's esophagus

Cancer of the lower esophagus develops almost exclusively in patients with Barrett's esophagus, an otherwise benign complication of esophageal reflux that affects approximately 3 million Americans. Although the prognosis of patients diagnosed with esophageal cancer is poor, the chances of successful treatment increase significantly if the disease is detected at an early dysplastic stage.

13 Apr 2010

Decrease in manic symptoms severity influences prescribing decisions for bipolar mania

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists say that the decrease in severity of manic symptoms is the attribute that most influences their prescribing decisions in bipolar mania. Clinical data and the opinions of interviewed thought leaders indicate that Eli Lilly's Zyprexa (olanzapine) has advantages in this attribute over AstraZeneca/Astellas's Seroquel (quetiapine), the sales-leading agent in the bipolar disorder drug market.

13 Apr 2010

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

13 Apr 2010

Lockheed Martin pledges $4M to aid UCLA Health System's Operation Mend program

The Lockheed Martin Corp. announced today a pledge of $4 million to benefit the UCLA Health System's Operation Mend program, which provides reconstructive surgeries and other health care needs to U.S. military personnel wounded in Iraq and Afghanistan.

13 Apr 2010

More treatment doesn't mean better outcomes, studies show

USA Today reports that "doctors have long been rewarded for providing more care, though more isn't always better. Three recent studies show that a doctor's instincts are no match for hard science." The studies include one of 800 high blood pressure patients that found opening clogged arteries with stents didn't lower blood pressure and actually raised side effects.

13 Apr 2010

Genes influence chronic kidney disease risk: Research

A team of researchers from the United States and Europe has identified more than a dozen genes that may play a role in the etiology of common forms of kidney disease. The team, known as the CKDGen Consortium, examined common variations in DNA sequences in more than 65,000 individuals of European descent. Common variations in several genes were found to be more frequent among people with poor kidney function or chronic kidney disease than in those with normal kidney function.

13 Apr 2010

Spring storms present a worse scenario for asthma and allergy patients

While spring storms get comprehensive coverage during weather casts, a close look at local allergy indexes make the thunder and lightning seem downright puny.

13 Apr 2010

Semel Institute for Neuroscience and Human Behavior awarded $14.9M for establishing new IPCN

The Semel Institute for Neuroscience and Human Behavior at UCLA has been awarded $14.9 million in American Recovery and Reinvestment Act funds to establish a center dedicated to interdisciplinary research on the role of genetic and environmental factors in neuropsychiatric and behavioral disorders.

13 Apr 2010

Stress and genetic factors may raise depression among medical interns

The percentage of clinicians who meet criteria for depression appears to increase significantly during medical internship, according to a report posted online that will appear in the June print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

13 Apr 2010

Link between IL-8, MIF gene polymorphisms and progression of atrophic gastritis and intestinal metaplasia

Atrophic gastritis and intestinal metaplasia are two important precursory lesions in the process of intestinal type gastric cancer. However, the precise mechanism of the progression of these two lesions is still unclear, a few studies have investigated the risk of host gene polymorphism on the atrophic gastritis and intestinal metaplasia, but all of them are limited by their one-time point screen.

13 Apr 2010

Despite international guidelines, wide variations exist in breast cancer care

A global study of nearly 10,000 women with early breast cancer has found wide variations in how they were treated, despite international consensus on best practice, according to the May issue of the British Journal of Surgery.

13 Apr 2010

Lean mass may decline among Alzheimer's patients

Lean mass—the weight of an individual's bones, muscles and organs without body fat—appears to decline among patients with Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.

13 Apr 2010

Research article reports association of chronic upper GI symptoms with diabetes

There are several papers which report the association of GI symptoms with diabetes. Epidemiological data regarding the association of GI symptoms with diabetes are, however, inconsistent, and the reported frequency of upper and lower GI symptoms varies among different ethnic groups/populations.

13 Apr 2010

Researchers evaluate new treatment for coronary heart disease

Some patients with heart muscles seriously affected by coronary heart disease may soon be able to benefit from an innovative treatment.

13 Apr 2010

Mylan Pharmaceuticals' ANDA for generic Wellbutrin SR receives FDA final approval

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP, (SR), 100 mg, 150 mg and 200 mg, the generic version of GlaxoSmithKline's antidepressant Wellbutrin SR®.

12 Apr 2010

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Losartan Potassium and Hydrochlorothiazide (HCTZ) Tablets 100 mg/12.5 mg, the generic version of Merck and Co., Inc.'s antihypertensive Hyzaar®.

12 Apr 2010

Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.

12 Apr 2010